The median progression free survival (PFS) achieved by the eight patients with nine secondary SM cases who received ALK‐TKI therapy was 5.6 months, while the median PFS of the 12 patients with 16 cases with nonsecondary SM who received next line treatment (nontailored ALK‐TKI or chemotherapy) was 5.1 months (Table 5). The gene discussed is ALK; the disease is systemic mastocytosis.